IDiyas

For the Inventor, By the Inventor

Harlow, United Kingdom

Steven Coulton

USPTO Granted Patents = 11

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Linton, GB (2001)
  • Horsham, GB (1997 - 2004)
  • Harlow, GB (2006 - 2011)

Company Filing History:

goldMedal11 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 1997-2011

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7919507 - N-aroyl cyclic amines (2011-04-05),
2. 7741329 - N-aroyl cyclic amines (2010-06-22),
3. 7468367 - Ethylene diamine derivatives and their use as orexin-receptor antagonists (2008-12-23),
4. 7432270 - N-aroyl cyclic amines (2008-10-07),
5. 7045619 - 2-(pyrazol-3-yl)carbapenem derivatives (2006-05-16),
6. 6699879 - Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists (2004-03-02),
7. 6596730 - Phenyl urea and phenyl thiourea derivatives (2003-07-22),
8. 6274594 - Isoquinoline derivatives and their therapeutical use (2001-08-14),
9. 6248754 - Substituted isoquinoline derivatives and their use as anticonvulsants (2001-06-19),
10. 5612477 - 2-(pyrazol-3-yl)carbapenem derivatives (1997-03-18),
11. 5606051 - 2-(pyrazol-3-yl)carbapenem derivatives (1997-02-25),

Title: Steven Coulton: A Pioneer in Pharmaceutical Innovations

Introduction

Steven Coulton is a remarkable inventor based in Harlow, GB, known for his contributions to pharmaceutical development. With an impressive portfolio of 11 patents, Coulton has made significant strides in the field of medicinal chemistry.

Latest Patents

Among his latest innovations are patent applications for N-aroyl cyclic amines. These derivatives, characterized by a specific formula, are disclosed for their potential use as pharmaceuticals. The focus on N-aroyl cyclic amines underscores Coulton's commitment to developing new therapeutic agents that could address various health challenges.

Career Highlights

Coulton's career is marked by his tenure at SmithKline Beecham Corporation, where he has been instrumental in advancing drug discovery and development. His work has not only contributed to the company's reputation as a leader in the pharmaceutical industry but also to the broader landscape of medical innovations.

Collaborations

Throughout his career, Steven Coulton has collaborated with esteemed colleagues, including Roderick Alan Porter and Amanda Johns. These collaborations have fostered an environment of innovation and creativity, leading to groundbreaking developments in pharmaceutical research.

Conclusion

In summary, Steven Coulton stands out as a dedicated inventor whose work has significant implications for pharmaceutical sciences. His latest patents reinforce his leadership in the field, and his collaborations with talented coworkers enhance the collective contributions to medicinal innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…